Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (Diluted Average): 2020-2023

Historic Shares Outstanding (Diluted Average) for Aytu Biopharma (AYTU) over the last 3 years, with Sep 2023 value amounting to $5.5 million.

  • Aytu Biopharma's Shares Outstanding (Diluted Average) rose 117.72% to $5.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $5.5 million, marking a year-over-year increase of 117.72%. This contributed to the annual value of $3.3 million for FY2023, which is 127.22% up from last year.
  • According to the latest figures from Q3 2023, Aytu Biopharma's Shares Outstanding (Diluted Average) is $5.5 million, which was up 64.14% from $3.3 million recorded in Q2 2023.
  • In the past 5 years, Aytu Biopharma's Shares Outstanding (Diluted Average) registered a high of $18.1 million during Q1 2021, and its lowest value of $1.3 million during Q3 2021.
  • Over the past 3 years, Aytu Biopharma's median Shares Outstanding (Diluted Average) value was $3.1 million (recorded in 2022), while the average stood at $5.3 million.
  • In the last 5 years, Aytu Biopharma's Shares Outstanding (Diluted Average) crashed by 91.79% in 2022 and then skyrocketed by 151.05% in 2023.
  • Over the past 4 years, Aytu Biopharma's Shares Outstanding (Diluted Average) (Quarterly) stood at $13.3 million in 2020, then tumbled by 90.06% to $1.3 million in 2021, then surged by 135.52% to $3.1 million in 2022, then surged by 117.72% to $5.5 million in 2023.
  • Its last three reported values are $5.5 million in Q3 2023, $3.3 million for Q2 2023, and $3.7 million during Q1 2023.